Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Care management intervention strategies
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Care management intervention strategies

1 evidence topic · 1 source

Stargardt’s Connected Research Network inaugural meeting report

“Increase access to comprehensive genetic testing globally, ensuring equitable participation across different regions and populations.” (opens the source at this quote in a new tab)